Kiora Pharmaceuticals
Open
$2.58
Prev. Close
$2.59
High
$2.58
Low
$2.58
Market Snapshot
$10.07M
-0.9
2.18
$16.02M
13
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 13 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Encinitas, California and currently employs 13 full-time employees. The company went IPO on 2015-02-13. The firm is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). The company is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Recently from Cashu
Kiora Pharmaceuticals: Summary of Recent Developments and Market Impact
Please provide the text you would like me to summarize, and I'll be happy to help.
Kiora Pharmaceuticals: Recent Developments and Market Insights
Please provide the content you would like me to summarize, and I'll be happy to help!
Kiora Pharmaceuticals: Innovating Ocular Therapies for Unmet Medical Needs in Biopharmaceuticals
Kiora Pharmaceuticals: Harnessing Innovation in the Biopharmaceutical Sector Kiora Pharmaceuticals stands at the forefront of the biopharmaceutical industry, focusing on the development of advanced th…
Kiora Pharmaceuticals Partners with RARE-X Consortium to Advance Rare Ocular Disorder Research
Kiora Pharmaceuticals Joins Forces to Transform Rare Ocular Disorder Research Kiora Pharmaceuticals, Inc. becomes a pivotal player in rare ocular disorder research by joining the Global Genes' RARE-X…